Below, we discuss CB Therapeutics’ patent application that covers methods of biosynthetically producing psilocybin. We also touch on mescaline, which MindMed is set to investigate in a Phase 1 trial. In the Weekend Reading section, we share fMRI data from two psilocybin trials and highlight a recent BBC documentary titled The Psychedelic Drug Trial. CB Therapeutics’ Patent Application Met with…


Previous articleWilliam Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’
Next articleMagicMed to Be Acquired by Nasdaq-Listed Company